These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells. Sugiyama A; Kageyama K; Murasawa S; Ishigame N; Niioka K; Daimon M Pituitary; 2015 Aug; 18(4):542-53. PubMed ID: 25280813 [TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors. Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192 [TBL] [Abstract][Full Text] [Related]
25. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Brough PA; Barril X; Beswick M; Dymock BW; Drysdale MJ; Wright L; Grant K; Massey A; Surgenor A; Workman P Bioorg Med Chem Lett; 2005 Dec; 15(23):5197-201. PubMed ID: 16213716 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors. Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402 [TBL] [Abstract][Full Text] [Related]
28. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046 [TBL] [Abstract][Full Text] [Related]
30. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522 [TBL] [Abstract][Full Text] [Related]
31. Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells. Wei Q; Ning JY; Dai X; Gao YD; Su L; Zhao BX; Miao JY Eur J Med Chem; 2018 Feb; 145():551-558. PubMed ID: 29339250 [TBL] [Abstract][Full Text] [Related]
32. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Massey AJ; Schoepfer J; Brough PA; Brueggen J; Chène P; Drysdale MJ; Pfaar U; Radimerski T; Ruetz S; Schweitzer A; Wood M; Garcia-Echeverria C; Jensen MR Mol Cancer Ther; 2010 Apr; 9(4):906-19. PubMed ID: 20371713 [TBL] [Abstract][Full Text] [Related]
33. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951 [TBL] [Abstract][Full Text] [Related]
34. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways. Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986 [TBL] [Abstract][Full Text] [Related]
36. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Holmes JL; Sharp SY; Hobbs S; Workman P Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495 [TBL] [Abstract][Full Text] [Related]
37. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Workman P; Burrows F; Neckers L; Rosen N Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464 [TBL] [Abstract][Full Text] [Related]